Phynova Group Ltd
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Inclusion Criteria: * Participants assigned female at birth (aged 40-60 years) will be recruited for the study. * Females ages 40-60 who are weight stable and with a self- reported Body Mass Index (BMI) between 18.5 to 35 kg/m2. * Willing to maintain their existing dietary and physical activity patterns throughout the study period. * Have received a medical physical screening (annual physical) within the last 12 months where blood markers for diabetes were taken and results were within the healthy range. * Self-reported \>40yrs in age and experiencing irregular periods. * Willing and able to…
Reducose® proprietary mulberry leaf extract, 250mg, 2/day with meals
Placebo matching capsules, Microcrystalline Cellulose
Arctuva estimate
Verify or correct the compensation shown for this listing.